Next Article in Journal
Revisiting the Advances in Isolation, Characterization and Secretome of Adipose-Derived Stromal/Stem Cells
Next Article in Special Issue
Anti-TNF Therapy in Crohn’s Disease
Previous Article in Journal
Injectable and Self-Healing Chitosan Hydrogel Based on Imine Bonds: Design and Therapeutic Applications
Previous Article in Special Issue
Transmembrane TNF and Partially TNFR1 Regulate TNFR2 Expression and Control Inflammation in Mycobacterial-Induced Pleurisy
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview

Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

1
Internal Medicine and Gastroenterology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, 00168 Roma, Italy
2
Gastroenterology Unit, Brotzu Hospital, 09121 Cagliari, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(8), 2199; https://doi.org/10.3390/ijms19082199
Received: 26 June 2018 / Revised: 19 July 2018 / Accepted: 24 July 2018 / Published: 27 July 2018
(This article belongs to the Special Issue Tumor Necrosis Factor (TNF))
  |  
PDF [1417 KB, uploaded 27 July 2018]
  |  

Abstract

Anti-tumor necrosis factor (TNF)-α agents represent an effective treatment for chronic inflammatory diseases. However, some concerns about their potentially undesirable effects on liver function have been reported. On the other hand, evidence of their therapeutic effects on certain liver diseases is accumulating. Many data showed the safety of anti-TNF-α in patients with chronic hepatitis B and C and in liver transplanted patients even if a strict follow-up and prophylaxis are recommended in well-defined subgroups. On the other side, anti-TNF-α-induced liver injury is not a rare event. However, it is often reversible after anti-TNF-α withdrawal. Anti-TNF-α agents have been tested in advanced stages of severe alcoholic hepatitis and non-alcoholic fatty liver disease. Limited data on the efficacy of anti-TNF-α in patients with autoimmune hepatitis and primary biliary cholangitis are also available. In this review, we explored the hepatic safety concerns in patients receiving anti-TNF-α agents with and without pre-existent hepatic diseases. In addition, the available evidence on their potential benefits in the treatment of specific hepatic diseases is discussed. View Full-Text
Keywords: infliximab; adalimumab; etanercept; certolizumab pegol; golimumab; hepatitis B virus; hepatitis C virus; drug-induced liver injury; non-alcoholic fatty liver disease; alcoholic hepatitis; autoimmune hepatitis infliximab; adalimumab; etanercept; certolizumab pegol; golimumab; hepatitis B virus; hepatitis C virus; drug-induced liver injury; non-alcoholic fatty liver disease; alcoholic hepatitis; autoimmune hepatitis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Lopetuso, L.R.; Mocci, G.; Marzo, M.; D’Aversa, F.; Rapaccini, G.L.; Guidi, L.; Armuzzi, A.; Gasbarrini, A.; Papa, A. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. Int. J. Mol. Sci. 2018, 19, 2199.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top